TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
Santin A, Corr B, Spira A, Willmott L, Butrynski J, Tse K, Patel J, Mekan S, Wu T, Dumbrava E. TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC). Journal Of Clinical Oncology 2023, 41: 5610-5610. DOI: 10.1200/jco.2023.41.16_suppl.5610.Peer-Reviewed Original ResearchTreatment-related adverse eventsClinical benefit rateProgression-free survivalDuration of responseWeeks of follow-upPt-based chemotherapyStable diseasePartial responseOpen-labelEndometrial cancerSafety profileFollow-upECOG PS 0-1Median duration of responseMedian progression-free survivalMedian study follow-upEC cohortAnti-PD-(L)1Metastatic solid tumorsStandard therapeutic regimensLimited treatment optionsStudy follow-upEfficacy of SGAntibody-drug conjugatesECOG PS